NASDAQ · SVA
Healthcare · Biotechnology
$6.47
Up+$0.00 (+0.00%)
Updated Aug 23, 2026, 12:38 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SVA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning SVA.
SVA research
Company profile and research snapshot.
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Sinovac Biotech (NASDAQ:SVA) reported quarterly losses of $(0.84) per share. This is a 1500 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $147.079 million in
Yahoo · Jul 15, 2026
BEIJING, July 15, 2026--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend.
Benzinga · Jun 15, 2026
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification
Yahoo · Jan 4, 2026
BEIJING, January 04, 2026--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP ("Zhonghua"), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and reg
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SVA.
No results
No recent SID articles mention SVA.
